Skip to main content
SpringerLink
Log in

Continuous intrathecal treatment with methotrexate via subcutaneous port: implication for leptomeningeal dissemination of malignant tumors

  • Clinical-Patient Studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Use of intrathecal (IT) chemotherapy combined with radiotherapy can extend survival of patients with untreated leptomeningeal dissemination of malignant tumors from one month to two to six months. The goal of the present study was to determine the effect of continuous IT (CIT) via a subcutaneous port that was placed using a neuronavigation system. Twenty patients with leptomeningeal dissemination (primary disease: 10 cancers, 6 gliomas and 4 lymphomas) were given 2–7 cycles of continuous IT (CIT) with methotrexate (MTX; 10 mg) administered into the lateral ventricle for 5 consecutive days biweekly. The concentration of MTX in the lateral ventricle was 7 to 10 × 10−6 M from Day 1 to 4. Response to this therapy included 6 patients with complete remission, 7 with progressive disease, and 7 with stable disease. Kaplan-Meier analysis revealed a median overall survival of 8 months while the overall survival rate for leptomeningeal specific death or for metastasis from cancer was 13 or 5 months, respectively. Complications of CIT with MTX were relatively low (<0.5%), and nausea and vomiting did not occur in any of the patients. In conclusion, CIT with 10 mg MTX via subcutaneous port for 5 days may improve the therapeutic effect and reduce the complications associated with treatment of leptomeningeal dissemination from malignant tumors. This would be a safe technique with possible implications that bear repeating more patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Chamberlain MC (1998a) Leptomeningeal metastases: A review of evaluation and treatment. J Neuro-oncol 37:271–284

    Article  CAS  Google Scholar 

  2. Chowdhary S, Chamberlain M (2005) Leptomeningeal metastases: current concepts and management guidelines. J Natl Compr Canc Netw 3:693–703

    PubMed  Google Scholar 

  3. DeAngelis LM, Boutros D (2005) Leptomeningeal metastasis. Cancer Invest 23:145–152

    Article  PubMed  Google Scholar 

  4. Bokstein F, Lossos A, Siegal T (1998) Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82:1756–1763

    Article  PubMed  CAS  Google Scholar 

  5. Boogerd W, van den Bent MJ, Koehler PJ et al (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer 40:2726–2733

    Article  PubMed  CAS  Google Scholar 

  6. Fizazi K, Asselain B, Vincent-Salomon A et al (1996) Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 77:1315–1323

    Article  PubMed  CAS  Google Scholar 

  7. Nakagawa H, Fujita T, Kubo S et al (1996) Ventriculolumbar perfusion chemotherapy with methotrexate and cytosine arabinoside for meningeal carcinomatosis: a pilot study in 13 patients. Surg Neurol 45:256–264

    Article  PubMed  CAS  Google Scholar 

  8. Orlando L, Curigliano G, Colleoni M et al (2002) Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res 22:3057–3059

    PubMed  Google Scholar 

  9. Yoshida S, Morii K (2005) Intrathecal chemotherapy for patients with meningeal carcinomatosis. Surg Neurol 63:52–55

    Article  PubMed  Google Scholar 

  10. Chamberlain MC, Kormanik P (1998b) Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 55:506–512

    Article  PubMed  CAS  Google Scholar 

  11. Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181

    Article  PubMed  Google Scholar 

  12. Collins JM (1983) Pharmacokinetics of intraventricular administration. J Neurooncol 1:283–291

    Article  PubMed  CAS  Google Scholar 

  13. Moser AM, Adamson PC, Gillespie AJ et al (1999) Intraventricular concentration times time (C × T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer 85:511–516

    Article  PubMed  CAS  Google Scholar 

  14. Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394–3402

    PubMed  CAS  Google Scholar 

  15. Jaeckle KA, Batchelor T, O’Day SJ et al (2002) An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 57:231–239

    Article  PubMed  Google Scholar 

  16. Phuphanich S, Maria B, Braeckman R et al (2007) A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 81:201–208

    Article  PubMed  CAS  Google Scholar 

  17. Yen J, Reiss FL, Kimelberg HK et al (1978) Direct administration of methotrexate into the central nervous system of primates. Part 2: Distribution of 3H methotrexate after intrathecal lumbar injection. J Neurosurg 48:895–902

    PubMed  CAS  Google Scholar 

  18. Chamberlain MC (2003) Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery 52:324–329

    Article  PubMed  Google Scholar 

  19. Shapiro WR, Young DF, Mehta BM (1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:161–166

    Article  PubMed  CAS  Google Scholar 

  20. Sandberg DI, Bilsky MH, Souweidane MM et al (2000) Ommaya reservoirs for the treatment of leptomeningeal metastasis. Neurosurgery 47:49–54

    Article  PubMed  CAS  Google Scholar 

  21. Fietz T, Thiel E, Baldus C et al (2002) Successful treatment of extracranially metastasized pineal gland germinoma with high-dose methotrexate. Ann Oncol 13: 1681–1685

    Article  PubMed  CAS  Google Scholar 

  22. Spreafico F, Massimino M, Gandola L et al (2005) Survival of adults treated for medulloblastoma using paediatric protocols. Eur J Cancer 41: 1304–1310

    Article  PubMed  Google Scholar 

  23. Boogerd W, vd Sande JJ, Moffie D (1988) Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 51:1277–1283

    Article  PubMed  CAS  Google Scholar 

  24. Boogerd W, Moffie D, Smets LA (1990) Early blindness and coma during intrathecal chemotherapy for meningeal carcinomatosis. Cancer 65:452–457

    Article  PubMed  CAS  Google Scholar 

  25. Brock S, Jennings HR (2004) Fatal acute encephalomyelitis after a single dose of intrathecal methotrexate. Pharmacotherapy 24:673–676

    Article  PubMed  Google Scholar 

  26. Chamberlain MC, Kormanik PA, Barba D (1997) Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87:694–699

    PubMed  CAS  Google Scholar 

  27. Dunkelman H, Earl HM, Twelves C (1991) Acute reversible neurological deficit following intrathecal chemotherapy. Cancer Chemother Pharmacol 27:329–330

    Article  PubMed  CAS  Google Scholar 

  28. Kastenbauer S, Wiesmann M, Pfister HW (2000) Cerebral vasculopathy and multiple infarctions in a woman with carcinomatous meningitis while on treatment with intrathecal methotrexate. J Neurooncol 48:41–45

    Article  PubMed  CAS  Google Scholar 

  29. Mahoney DH Jr, Shuster JJ, Nitschke R et al (1998) Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy—a Pediatric Oncology Group study. J Clin Oncol 16:1712–1722

    PubMed  CAS  Google Scholar 

  30. Sakamaki H, Onozawa Y, Yano Y et al (1993) Disseminated necrotizing leukoencephalopathy following irradiation and methotrexate therapy for central nervous system infiltration of leukemia and lymphoma. Radiat Med 11:146–153

    PubMed  CAS  Google Scholar 

  31. Shore T, Barnett MJ, Phillips GL (1990) Sudden neurologic death after intrathecal methotrexate. Med Pediatr Oncol 18:159–161

    Article  PubMed  CAS  Google Scholar 

  32. Fleischhack G, Jaehde U, Bode U (2005) Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet 44:1031

    Article  Google Scholar 

  33. Schug SA, Saunders D, Kurowski I et al (2006) Neuroaxial drug administration: a review of treatment options for anaesthesia and analgesia. CNS Drugs 20:917–933

    Article  PubMed  CAS  Google Scholar 

  34. Grossman SA, Finkelstein DM, Ruckdeschel JC et al (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11:561–569

    PubMed  CAS  Google Scholar 

  35. Gammon DC, Bhatt MS, Tran L et al (2006) Intrathecal topotecan in adult patients with neoplastic meningitis. Am J Health Syst Pharm 63:2083–2086

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank H. Shinoura for assistance with manuscript preparation. This work was supported by the Japanese Foundation for Multidisciplinary Treatment of Cancer.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Komagome Metropolitan Hospital, 3-18-22 Hon-Komagome, Bunkyo-ku, Tokyo, 113-8677, Japan

    Nobusada Shinoura, Yusuke Tabei, Ryozi Yamada, Kuniaki Saito & Masamichi Takahashi

Authors
  1. Nobusada Shinoura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yusuke Tabei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryozi Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kuniaki Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masamichi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nobusada Shinoura.

Additional information

N. Shinoura and Y. Tabei have equally contributed to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shinoura, N., Tabei, Y., Yamada, R. et al. Continuous intrathecal treatment with methotrexate via subcutaneous port: implication for leptomeningeal dissemination of malignant tumors. J Neurooncol 87, 309–316 (2008). https://doi.org/10.1007/s11060-007-9511-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-007-9511-3

Keywords

Search

Navigation